Makoto Nishimura

Closest collaborators

The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Yoko Matsuda · 3 shared papers, 2018–2023 · strength 0.36
   • Paper STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-ref… DOI 10.1016/j.eclinm.2022.101731↗
   • Paper Overexpression of carbohydrate sulfotransferase 15 in pancreatic cancer stroma is associated with worse prognosis. DOI 10.3892/ol.2019.10764↗
   • Paper Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival… DOI 10.1016/j.gie.2017.10.030↗
2. Tomio Arai · 3 shared papers, 2018–2023 · strength 0.36
   • Paper STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-ref… DOI 10.1016/j.eclinm.2022.101731↗
   • Paper Overexpression of carbohydrate sulfotransferase 15 in pancreatic cancer stroma is associated with worse prognosis. DOI 10.3892/ol.2019.10764↗
   • Paper Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival… DOI 10.1016/j.gie.2017.10.030↗
3. Naohisa Yahagi · 2 shared papers, 2018–2023 · strength 0.24
   • Paper STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-ref… DOI 10.1016/j.eclinm.2022.101731↗
   • Paper Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival… DOI 10.1016/j.gie.2017.10.030↗
4. Takao Itoi · 2 shared papers, 2018–2023 · strength 0.24
   • Paper STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-ref… DOI 10.1016/j.eclinm.2022.101731↗
   • Paper Effects of EUS-guided intratumoral injection of oligonucleotide STNM01 on tumor growth, histology, and overall survival… DOI 10.1016/j.gie.2017.10.030↗
5. Toshio Fujisawa · 1 shared paper, 2023 · strength 0.16
   • Paper STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-ref… DOI 10.1016/j.eclinm.2022.101731↗
6. Hiroyuki Isayama · 1 shared paper, 2023 · strength 0.16
   • Paper STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-ref… DOI 10.1016/j.eclinm.2022.101731↗
7. Motohiko Kato · 1 shared paper, 2023 · strength 0.16
   • Paper STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-ref… DOI 10.1016/j.eclinm.2022.101731↗
8. Kazuki Takakura · 1 shared paper, 2023 · strength 0.16
   • Paper STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-ref… DOI 10.1016/j.eclinm.2022.101731↗
9. Shomei Ryozawa · 1 shared paper, 2023 · strength 0.16
   • Paper STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-ref… DOI 10.1016/j.eclinm.2022.101731↗
10. Hideyuki Saya · 1 shared paper, 2023 · strength 0.16
    • Paper STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-ref… DOI 10.1016/j.eclinm.2022.101731↗
11. Toshiyuki Ishiwata · 1 shared paper, 2019 · strength 0.11
    • Paper Overexpression of carbohydrate sulfotransferase 15 in pancreatic cancer stroma is associated with worse prognosis. DOI 10.3892/ol.2019.10764↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.